Pharma leaders turn to integrated scenario modeling as US MFN pricing reshapes global launch strategies

The article explains that integrated scenario modeling is becoming a key tool for pharmaceutical executives facing pricing uncertainty and the complexities of worldwide product launches.

It references a 2025 executive order by President Trump that required drugmakers to price new U.S. medicines at levels comparable to other high‑income countries and to sell existing drugs to Medicaid at most‑favored‑nation rates. By the end of 2025, most large manufacturers had signed voluntary agreements, covering roughly 89% of the branded market.

Early signs indicate the MFN pricing rule is linked to a drop in new drug launches in Europe, with an estimated 35% year‑over‑year decline. The piece suggests that such policy changes are driving companies to adopt more sophisticated modeling approaches.

Scenario modeling is presented as a way for firms to forecast pricing outcomes and coordinate launch strategies across regions amid the shifting regulatory landscape.